{
    "Trade/Device Name(s)": [
        "DRI\u00ae Hemoglobin A1c Assay",
        "DRI\u00ae Hemoglobin A1c Calibrators"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K053411",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "KRZ"
    ],
    "Summary Letter Date": "February 3, 2006",
    "Summary Letter Received Date": "December 7, 2005",
    "Submission Date": "November 30, 2005",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous immunoassay",
        "Light scattering agglutination",
        "Spectrophotometric measurement"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Hemoglobin A1c Assay and calibrators for quantitative determination of HbA1c in whole blood using homogeneous immunoassay on automated chemistry analyzers",
    "Indications for Use Summary": "Quantitative determination of Hemoglobin A1c in human whole blood using automated clinical chemistry analyzers to aid in monitoring long-term blood glucose control in individuals with diabetes mellitus",
    "fda_folder": "Hematology"
}